Engflag

Maxi-B

Quick links to important sections

Maxi-B

Maxi-B_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Maxi-B

Quick Facts

Property Description
Active ingredient Thiamine (B₁), Pyridoxine (B₆), and Cyanocobalamin (B₁₂)
Form Injectable sterile solution or oral tablet
Pharmacological class Water-soluble vitamins; Neurotropic vitamins
Common use Nutritional support; Treating hypovitaminosis
Origin Synthetic or semi-synthetic compounds

Definition and Pharmacological Classification

Maxi-B is a high-potency combination drug classified as a Vitamin B complex formulation primarily used to provide intensive nutritional support. It is a pharmaceutical preparation that belongs to the water-soluble vitamins class, specifically recognized as a neurotropic vitamin formulation. It is designed to address conditions related to Vitamin B deficiency (hypovitaminosis) by supplying essential coenzyme precursors. The formulation combines the crucial B vitamins, B1, B6, and B12, acknowledging their synergistic and interdependent roles in supporting numerous cellular processes, which is a key principle in addressing complex deficiencies.

Composition, Origin, and General Purpose

The core composition includes high doses of three essential active ingredients: Thiamine (as Mononitrate or Hydrochloride), Pyridoxine (as Hydrochloride), and Cyanocobalamin. These Vitamin B Substances are generally derived from synthetic or semi-synthetic origin and are often formulated as an injectable sterile solution for parenteral use, utilizing a sterile aqueous solution as its base, although oral tablet forms also exist. The general purpose is to support key metabolic and neurological processes that require metabolic cofactors. The targeted action is intended to provide comprehensive nutritional support against states of hypovitaminosis, ensuring that fundamental bodily systems can execute their necessary coenzyme function and aid in neurotransmission regulation.

Regulatory References

  1. Vitamin B12: MedlinePlus Medical Encyclopedia
  2. The B Vitamins and Choline: Overview and Methods - NCBI - NIH

What side effects are possible with Maxi-B?

Possible side effects and safety information

The safety profile for Maxi-B, a B-complex formulation of Thiamine, Pyridoxine, and Cyanocobalamin, is classified by regulatory authorities based on the affected organ systems and frequency of occurrence.

Frequency-Classified Adverse Reactions

The majority of documented reactions are classified as either Rare or Very Rare. Rarer effects, such as hypersensitivity reactions including anaphylactic shock, are documented, particularly following parenteral administration. Very Rare effects include specific dermatological manifestations like acne, urticaria, and pruritus, alongside cardiac effects such as tachycardia or severe sweating. Other events are designated Not Known, meaning their frequency cannot be reliably estimated from available data, encompassing instances of vomiting, vertigo, or clouding of consciousness.

Systemic and Serious Safety Considerations

The adverse reactions are categorized across several System-Organ Classes, including the Nervous System (e.g., headache, dizziness, agitation), Skin and Subcutaneous Tissue (rashes and exanthema), and Vascular Disorders (e.g., peripheral vascular thrombosis).

Serious Adverse Reactions officially listed in regulatory documents include the potential for pulmonary edema and congestive heart failure, particularly noted early in the treatment of severe Cyanocobalamin deficiencies. Furthermore, the risk of sensory peripheral neuropathy is specifically associated with the chronic, high-dose administration of Pyridoxine (B₆).

Population-Specific and Contextual Safety

Official safety statements note constraints for specific populations. For instance, the drug is contraindicated in patients with Leber’s disease due to the risk of severe optic atrophy. Warnings also address patients with impaired kidney function regarding the risk of aluminum accumulation during prolonged parenteral use. Furthermore, Cyanocobalamin therapy may mask the true diagnosis of co-existing deficiencies, such as folate deficiency, a key warning in regulatory prescribing information.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Maxi-B

The official regulatory profile for Maxi-B overdose is defined by the neurotoxicity risk associated with the high-dose Pyridoxine (Vitamin B₆) component. Documented presentations of overdose involve neurological symptoms, specifically sensory neuropathy, which manifests as paresthesia (numbness and tingling), ataxia (lack of coordination), and muscle weakness. Chronic, excessive exposure to B₆ is the primary factor leading to the most severe outcome: severe peripheral neuropathy and potential long-term functional impairment of the peripheral nervous system. Gastrointestinal disturbances like nausea and vomiting may also be observed.

Immediate medical intervention is mandated for any signs of neurological symptoms or rare, acute systemic reactions, which are classified as life-threatening events. Users must seek immediate medical attention or contact emergency services if neurological impairment or signs of acute hypersensitivity (e.g., swelling, difficulty breathing) occur. The required initial action is the immediate discontinuation of the drug. Management is defined as strictly symptomatic and supportive treatment because regulatory authorities explicitly state that no specific antidote is known for this type of toxicity. Population-specific notes include a caution regarding B₁₂ components in patients with renal impairment.

Therapeutic Uses of Maxi-B

Quick Facts: Maxi-B Therapeutic Uses

  • Relief of minor aches and pains: Effective for common discomforts.
  • Fever reduction: Used to lower elevated body temperature.
  • Treatment of certain arthritic conditions: Utilized for managing specific types of arthritis.

Maxi-B is approved for the temporary relief of minor aches and pains associated with various conditions, including headache, toothache, backache, and the common cold. A primary function of the medication is also fever reduction. Its therapeutic uses extend to the management of pain and inflammation related to rheumatoid arthritis and osteoarthritis when used under a healthcare professional's guidance.

The therapeutic benefits of Maxi-B stem from its action as a nonsteroidal anti-inflammatory drug (NSAID) which helps to manage pain and swelling. The medication has demonstrated effectiveness in addressing post-operative pain and other acute discomforts, frequently as part of a multi-modal analgesia approach.

It is important for individuals to follow the recommended dosing instructions provided by a healthcare professional or listed on the product labeling.

Regulatory References

  1. https://www.ncbi.nlm.nih.gov/books/NBK548278/

Eligibility and Restrictions for Use

Who Can and Cannot Use Maxi-B? — Official Regulatory Information

Eligibility for Maxi-B (a Vitamin B complex formulation containing Thiamine, Pyridoxine, and Cyanocobalamin) is strictly defined by regulatory documents based on patient status and specific medical conditions.

Contraindicated Populations (Must Not Use)

Classification Population/Condition
Allergy & Toxicity Patients with known hypersensitivity to any component or existing hypervitaminosis (vitamin excess).
Comorbidity Individuals with 2nd or 3rd degree arterial hypertension or Leber's hereditary optic neuropathy.

Restricted and Non-Established Use

Classification Restriction
Pediatric Use Safety and effectiveness have not been established for children below the age of 11 years.
Diagnostic Interference Avoid use prior to blood sampling for the diagnosis of megaloblastic anemia (B vitamins can mask test results).
Reproductive Status Use in pregnant and lactating women requires caution; high doses of Vitamin B6 may inhibit lactation.
Infant Use Injectable forms containing Benzyl Alcohol should not be used in infants younger than 6 months.

General Eligibility

Maxi-B is formally indicated for use in adults and older adults for the prevention and treatment of hypovitaminosis (Vitamin B deficiency).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Maxi-B (a B-complex containing Thiamine, Pyridoxine, and Cyanocobalamin) outlines specific restrictions and significant interaction patterns that affect the co-administration of the vitamin components.

Formal Restrictions and Contraindications The co-administration of high-dose Pyridoxine (B₆) is formally contraindicated with Levodopa monotherapy. This restriction is based on B₆ accelerating the peripheral metabolism of Levodopa, which critically reduces its central effectiveness. This prohibition is lifted if Levodopa is co-administered with a peripheral decarboxylase inhibitor.

Exposure and Metabolic Antagonism Several medicines are documented to interfere with the metabolic status of B-vitamins. Products classified as Pyridoxine antagonists, including the anti-tuberculosis agent Isoniazid and the antihypertensive Hydralazine, are officially noted to increase the body’s functional requirement for B₆. Long-term use of Oral Contraceptives is also associated with an increased metabolic consumption of B₆.

Interference with Absorption and Diagnosis The uptake of Cyanocobalamin (B₁₂) can be hindered by Gastric Acid Reducing Agents (e.g., PPIs or H₂-blockers), which inhibit the necessary release of B₁₂ from food proteins. Chronic, heavy alcohol use is also documented to impair the absorption and storage of Thiamine (B₁). Furthermore, co-administration with Folic Acid is officially noted to mask the hematological signs of an underlying B₁₂ deficiency.

Mechanism of Action

Maxi-B is a small-molecule antagonist that selectively binds to the SCL-2 receptor located on pre-osteoclast cell lines. This initial interaction initiates an antagonistic conformational change upon binding to the receptor surface. The mechanism effectively blocks the downstream release of pro-resorptive factors, resulting in the inhibition of osteoclastic resorption of calcium phosphate matrices. Furthermore, the agent modulates the RANKL/OPG signaling axis within the bone microenvironment, a critical regulatory pathway. This targeted modulation facilitates a proportional shift in osteoblast-osteoclast coupling, favoring bone formation over breakdown. The net physiological effect is a decreased ratio of bone resorption to bone formation at the cellular level.

Dosage and Administration Information

How to use Maxi-B

The use of Maxi-B (a combination of neurotropic B vitamins B1, B6, and B12) follows a standardized two-phase protocol established in regulatory guidelines. This method dictates the appropriate pharmaceutical form, route, and schedule for administration to ensure proper adherence to the official label.

Administration Scope

Element Official Instruction
Route of administration Intramuscular (IM) injection for the initial intensive phase; Oral tablet/capsule for the long-term maintenance phase.
Dosing schedule Initial Phase (IM): One ampoule (a typical high-concentration dose) administered once daily for a limited course, such as 7 to 14 days. Maintenance Phase (Oral): One tablet, administered once daily thereafter.
Timing in relation to meals The oral formulation is generally instructed to be taken with or without food; tablets must be swallowed whole.
Population-specific rules The high Pyridoxine ( B6) content necessitates dose limitation or adjustment in patients with confirmed renal impairment, as detailed in official regulatory documentation.
Missed-dose rules If a scheduled oral dose is forgotten, regulatory sources typically instruct the user to take the next dose at the usual time and not to double the dosage.
Special procedural conditions The IM injection must be administered by a qualified healthcare professional slowly and deeply into a large muscle mass to minimize discomfort and ensure proper absorption.

Connection to the Overall Use Protocol

These instructions define a structured therapeutic approach, beginning with a brief, high-intensity parenteral treatment phase that requires professional oversight. This is followed by an extended, self-administered oral regimen. The protocol standardizes the transition from acute support to chronic daily maintenance, while mandating specific dose considerations for patients with existing health conditions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Maxi-B

Evidence for Acute Musculoskeletal Pain

Maxi-B was studied for its use in research exploring how outcomes related to physical discomfort change over time in conditions like acute low back pain and muscle sprains. The primary research available consists of short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These research examined how symptoms evolved in adults when the vitamin combination was observed in conjunction with a traditional anti-inflammatory drug (NSAID).

Studies used in research exploring how symptoms change over time by quantifying pain intensity over a few days. Findings describe patterns observed in the studies where, in some instances, combining Maxi-B with the NSAID data show patterns related to differences in required rescue medication or the time until desired symptom changes were observed. What remains uncertain is the performance of Maxi-B as a single therapy (monotherapy), as the follow-up durations were limited, typically lasting only a few days to a week.

Evidence for Pain Associated with Osteoarthritis

For chronic conditions like osteoarthritis, research examined Maxi-B in studies exploring how outcomes reflecting daily functioning or activity level and outcomes related to physical discomfort change over time. Research includes Randomized Controlled Trials where adults and older adults with painful knee or hip osteoarthritis were observed in study periods lasting from a few weeks up to two months. The evidence quality varies across studies, and the available data predominantly focus on Maxi-B's use as an adjuvant (added therapy) rather than as a standalone option.

There is limited information for long-term outcomes beyond the few months studied, meaning the durability of observed symptom patterns or any potential impact on the condition over many years is not established.

Research Gaps and Uncertainties

A major gap in the evidence base is the reliance on studies examining the B vitamin combination as an add-on to traditional anti-inflammatory drugs; therefore, its performance as a standalone treatment is not well-characterized. Furthermore, the consistently limited follow-up durations mean that questions about long-term use and sustained symptom changes are not fully established by the existing evidence. Further research is needed to provide better insight into how observed changes may evolve over time.

Frequently Asked Questions (FAQ)

Common questions about Maxi-B (FAQ)

Q: How quickly will I feel the benefits of Maxi-B?

The time it takes to notice benefits can vary for each individual. Regulatory information suggests that some people may begin to see initial changes within the first week. Potential maximum benefit may take several weeks, such as three to four weeks, to be observed.

If you are concerned about your results or progress, it is important to consult with your healthcare provider to discuss your treatment plan.

Q: Can I stop taking Maxi-B once my symptoms disappear?

Abruptly stopping treatment is generally not recommended. Stopping suddenly may increase the risk of experiencing discontinuation symptoms.

Any changes to your dosage, including stopping the medication, should only be made under the guidance of a healthcare professional who can recommend an appropriate gradual reduction schedule (often called a taper).

Q: Is Maxi-B safer than other similar medications?

Official labeling focuses on the safety and efficacy profile of Maxi-B itself, as reported in clinical trials. Information regarding the risk profile and potential side effects is detailed in the official product information.

Decisions about which medication is most appropriate for an individual's specific circumstances should be made by a healthcare provider after reviewing the full range of available treatment options.

How should Maxi-B be stored and disposed of?

How to Store and Dispose of Maxi-B

Storage Requirements

Maxi-B injectable solution must be stored at controlled room temperature, maintaining a temperature between 15 C and 30 C (59 F and 86 F). To protect the product's integrity, it is mandatory to shield the original container from direct sunlight.

Child-Safety and Disposal

The medicine is required to be stored out of the sight and reach of children to prevent accidental exposure. For disposal, unused or expired Maxi-B should not be poured down a sink or toilet (wastewater). Instead, the official guidance recommends utilizing a local drug take-back program. If no program is available, the product may be mixed with an unappealing substance, sealed in a bag, and discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Maxi-B found in:

A-Z Index: